FADS2 and Myocardial fibrosis: In this post-hoc analysis of the OMEGA-REMODEL trial, we hypothesized that personalized profiling of FADS2 genetic polymorphisms would result in an improved selection of patients who would respond favorably to O-3FA therapy by attenuating adverse left ventricular functional deterioration and non-infarct myocardial fibrosis during the convalescent healing phase following AMI.